Thus, pemafibrate attenuates postprandial hyperlipidemia by suppression of chylomicron synthesis and secretion via inhibition of cholesterol absorption via NPC1L1 as well as PPARα activation in the small intestines. Here, NPC1L1 is linked to hyperlipidemia.